This August, the 9th IPF Summit returns as the industry’s must attend summit, providing an essential platform for the entire community to gather and dissect the latest breakthroughs and setbacks, to shape the future of pulmonary fibrosis drug development.

Be one of the first to view the agenda here: https://ter.li/moky9n

A Snapshot of What Awaits You in 2025:

• Case Study on the Path to Phase 3 Success: Hear directly from Boehringer Ingelheim’s Susanne Stowasser and Matthew Thomas as they unpack nerandomilast’s journey from discovery through to clinical success
• Brand-New From Setbacks to Solutions Seminar Afternoon: Analyze recent Phase 2 and 3 trial failures from with expert insights from Pfizer and former leaders at Galecto and Galapagos
• Navigating a Shifting Treatment Landscape: Explore how clinical benchmarks are changing and how new therapies must position themselves, with input from Boehringer Ingelheim, BMS, and Insilico Medicine
• Enhancing Preclinical Confidence: Discover what a high-confidence translational package looks like in 2025, featuring case studies from GSK, Boehringer Ingelheim, and others.

If ever there was a time to invest in this community and a conference, it’s now. Join us to gain the full spectrum of insight needed to bring better IPF therapies to patients – faster.

Find all the information needed here: https://ter.li/moky9n